Best of ASCO - 2014 Annual Meeting

 

Welcome

New Targets and New Technologies (IO)

Developmental Immunotherapy and Tumor Immunobiology

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
2D and 3D thermally bioprinted human MCF-7 breast cancer cells: A promising model for drug discovery.

Aleli Campbell

2605

A donor-dependent in vivo model for single agent and drug combination cytokine release syndrome safety evaluation.

James G. Keck

2612

A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.

Rosalyn A. Juergens

2599

A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE).

Aung Naing

TPS2668

A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).

Julio Antonio Peguero

TPS2667

A novel dual inhibitor of IDO and TDO, CMG017, potently suppresses the kynurenine pathway and overcomes resistance to immune checkpoint inhibitors.

Chan Kim

e14228

A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses.

Roger B. Cohen

2611

A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy.

Shubham Pant

TPS2670

A phase II study of cryoablation (cryo) of an enlarging tumor in patients (pts) with advanced lung cancer or melanoma receiving post-progression immune checkpoint inhibition (ICI).

Meghan Mooradian

e14243

A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).

Salomon M. Stemmer

2503

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

John D. Powderly

2604

An innovative combined immunization platform for personalized cancer immunotherapy.

Jessica Matta

e14225

An open label, multicenter, phase 1b/2 study of rebastinib (DCC-2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patients with advanced or metastatic solid tumors.

Anthony W. Tolcher

TPS2666

An umbrella for the cytokine storm: Enabling precision detection of CRS in CAR-T therapy.

Qimin Quan

e14223

Application of artificial intelligence to predict a new class of novel synthetic lethal targets.

Spyro Mousses

2598

Applying machine learning strategy for microsatellite status detection in plasma sample type.

Lili Zhao

e14219

Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.

Peter A. Kaufman

2606

Collagen affinity improves efficacy and safety of antibody and cytokine cancer immunotherapy.

Ako Ishihara

e14232

Correlation of radiosensitivity of lung carcinoma to CD137L endogenous expression levels.

Swati Girdhani

e14229

CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.

Aung Naing

2513

Determination of the recommended phase II dose of birinapant in combination with pembrolizumab: Results from the dose-escalation phase of BPT-201.

Russell J. Schilder

2506

Feasibility study of microbial ecosystem therapeutics (MET-4) to evaluate effects of fecal microbiome in patients on immunotherapy (MET4-IO).

Tira Jing Ying Tan

TPS2664

First-in-human (FIH) trial evaluating immune activation and safety of PIN- 2 administered intravenously to patients with advanced solid tumors.

Colin Bier

2600

First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts).

Alexandra Leary

2521

Immune profiling of tumor-infiltrating T cells using mass cytometry.

David Roumanes

2607

Immunological impact of canerpaturev (C-REV, formerly HF10), an oncolytic viral immunotherapy, with or without ipilimumab (Ipi) for advanced solid tumor patients (pts).

Takayuki Nakayama

2610

Introduction of a variable electrostatic field for targeted drug application following intraperitoneal aerosol chemotherapy (PIPAC).

Veria Khosrawipour

e14211

MDNA109: Effect of an interleukin-2 superkine on CD8 T-cell properties in the tumor microenvironment.

Moutih Rafei

e14220

Microsatellite instability assessment of FFPE tumor samples through targeted next-generation sequencing.

Elaine Wong-Ho

e14213

Modified ketogenic diet in solid tumors: A Veteran Affairs Pittsburgh Healthcare System case series.

Jocelyn Lai Tan

e14217

Monoclonal microbial EDP1503 to induce antitumor responses via gut-mediated activation of both innate and adaptive immunity.

Humphrey Athelstan Gardner

e14241

Novel monoclonal antibody therapeutics for metastatic castration resistant prostate cancer.

Maloy Ghosh

e14222

Occupational health risk of pressurized intra-peritoneal aerosol chemotherapy (PIPAC) via endoscopical microcatheter system.

Tanja Khosrawipour

e14231

Oncolytic and protective effect of strain no. 228 of a new rotavirus group in the Reoviridae family on В16/F10 melanoma growth in experiment.

Sergey A. Kolpakov

e14210

Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.

Matthew Reilley

TPS2669

Phase 1/1b multicenter trial of TPST-1120, a peroxisome proliferator-activated receptor alpha (PPARα) antagonist as a single agent (SA) or in combination in patients with advanced solid tumors.

Ginna Laport

TPS2665

Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors.

Toshio Shimizu

2609

Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.

Jian-Ming Xu

2608

Possible viral oncolysis by members of the Reoviridae and Paramyxoviridae families (an in vitro study).

Anastasia O. Sitkovskaya

e14212

Preclinical development of combination therapy targeting the dominant cytokine interleukin-1β for renal cell carcinoma.

David Henry Aggen

e14237

Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.

Michael Rahman Shafique

2601

Recycling of residual liquid drug formation following pressurized intra-peritoneal aerosol chemotherapy (PIPAC).

Haris Chaudhry

e14215

Reovirus strain R-92 in in vitro generation of tumor-specific T-lymphocytes.

Anastasia O. Sitkovskaya

e14216

Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies.

Ahmad Awada

2504

Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation.

Anthony B. El-Khoueiry

2602

Some characteristics of cancer-testis gene expression regulation in colorectal cancer.

Kristina I. Soldatova

e14233

Spatially-resolved, multiplexed quantification of protein and mRNA distribution and abundance in colorectal cancer tumor microenvironment with multiple modalities of NanoString GeoMx Digital Spatial Profiler.

Gokhan Demirkan

e14218

THOR-707: Using synthetic biology to reprogram the therapeutic activity of interleukin-2 (IL-2).

Marcos E Milla

2603